Retrophin Appoints Noah Rosenberg Chief Medical Officer

Xconomy San Diego — 

Noah Rosenberg has joined Retrophin (NASDAQ: RTRX) as chief medical officer. Rosenberg comes to the San Diego biotech from Fairfield, NJ-based Medimetriks Pharmaceuticals, where he was chief medical officer. Retrophin’s drug pipeline includes late-stage drug candidates fosmetpantotenate, an experimental treatment for the rare neurological disorder pantothenate kinase-associated neurodegeneration, and sparsentan, a drug for a rare kidney disease that Retrophin licensed from Ligand Pharmaceuticals (NASDAQ: LGND) in 2012.